Combined Vorinostat and Chloroquine Inhibit Sodium–Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo

ML Read, K Brookes, L Zha, S Manivannan, J Kim… - Clinical Cancer …, 2024 - AACR
Purpose: Patients with aggressive thyroid cancer are frequently failed by the central therapy
of ablative radioiodide (RAI) uptake, due to reduced plasma membrane (PM) localization of …
被引用次数：3 相关文章

Combined Vorinostat and Chloroquine Inhibit Sodium–Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo

ML Read, K Brookes, L Zha, S Manivannan, J Kim… - Clinical Cancer …, 2024 - AACR
Purpose: Patients with aggressive thyroid cancer are frequently failed by the central therapy
of ablative radioiodide (RAI) uptake, due to reduced plasma membrane (PM) localization of …

Combined Vorinostat and Chloroquine Inhibit Sodium Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo

ML Read, K Brookes, L Zha, S Manivannan… - … cancer research: an …, 2023 - kclpure.kcl.ac.uk
PURPOSE: Patients with aggressive thyroid cancer are frequently failed by the central
therapy of ablative radioiodide (RAI) uptake, due to reduced plasma membrane (PM) …

Combined Vorinostat and Chloroquine Inhibit Sodium-Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo

ML Read, K Brookes, L Zha… - … : an official journal …, 2024 - pubmed.ncbi.nlm.nih.gov
Purpose Patients with aggressive thyroid cancer are frequently failed by the central therapy
of ablative radioiodide (RAI) uptake, due to reduced plasma membrane (PM) localization of …

Combined Vorinostat and Chloroquine Inhibit Sodium–Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo

ML Read, K Brookes, L Zha… - Clinical Cancer …, 2024 - ohiostate.elsevierpure.com
Purpose: Patients with aggressive thyroid cancer are frequently failed by the central therapy
of ablative radioiodide (RAI) uptake, due to reduced plasma membrane (PM) localization of …
[PDF] core.ac.uk

[PDF][PDF] Combined Vorinostat and Chloroquine Inhibit Sodium Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo

M Read, K Brookes, L Zha, S Manivannan, J Kim… - core.ac.uk
Thyroid cancer is the most rapidly increasing cancer in the USA, with a clear unmet clinical
49 need due to insufficient sodium iodide symporter (NIS) activity limiting radioiodide (RAI) …

Combined Vorinostat and Chloroquine Inhibit Sodium-Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo.

ML Read, K Brookes, L Zha, S Manivannan… - … Cancer Research: an …, 2024 - europepmc.org
Purpose Patients with aggressive thyroid cancer are frequently failed by the central therapy
of ablative radioiodide (RAI) uptake, due to reduced plasma membrane (PM) localization of …
[PDF] birmingham.ac.uk

[PDF][PDF] Combined Vorinostat and Chloroquine Inhibit Sodium Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo

M Read, K Brookes, L Zha, S Manivannan, J Kim… - research.birmingham.ac.uk
Thyroid cancer is the most rapidly increasing cancer in the USA, with a clear unmet clinical
49 need due to insufficient sodium iodide symporter (NIS) activity limiting radioiodide (RAI) …
[HTML] nih.gov

[HTML][HTML] Combined Vorinostat and Chloroquine Inhibit Sodium Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo

ML Read, K Brookes, L Zha, S Manivannan… - … cancer research: an …, 2024 - ncbi.nlm.nih.gov
Purpose Patients with aggressive thyroid cancer are frequently failed by the central therapy
of ablative radioiodide (RAI) uptake, due to reduced plasma membrane (PM) localization of …

Combined Vorinostat and Chloroquine Inhibit Sodium Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo

M Read, K Brookes, L Zha… - Clinical Cancer …, 2023 - research.birmingham.ac.uk
Purpose Patients with aggressive thyroid cancer are frequently failed by the central therapy
of ablative radioiodide (RAI) uptake, due to reduced plasma membrane (PM) localization of …